Related Experiment Videos
[Blood platelet changes in myeloproliferative disorders]
G D'Angelo1, D Calvano, C Giardini
1Presidio Ospedaliero di Somma Lombardo, U.S.S.L. n. 6 - Gallarate, Varese.
Minerva Medica
|October 1, 1988
Summary
Platelet abnormalities in myeloproliferative disorders (MPD) can lead to serious bleeding or clotting. Reduced platelet activity in MPD may indicate a poor prognosis, but standard tests are insufficient for early diagnosis.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Context:
- Myeloproliferative disorders (MPD) are clonal stem cell disorders.
- Platelets play a crucial role in hemostasis and thrombosis.
- MPD are associated with significant morbidity and mortality, often due to platelet-related complications.
Purpose:
- To examine morphofunctional platelet alterations in MPD.
- To investigate the potential causes of thromboembolism and hemorrhage in MPD patients.
- To evaluate the prognostic value of platelet mitogenic activity and the diagnostic utility of standard platelet function tests.
Summary:
- MPD exhibit diverse platelet anomalies, including morphological changes, storage pool disease, membrane defects, altered arachidonic acid metabolism, and von Willebrand factor abnormalities.
- These platelet dysfunctions contribute to a high incidence of bleeding and thrombotic events in MPD.
- Reduced platelet mitogenic activity is a marker of the anomalous megakaryocytic clone transformation and may hold prognostic significance.
Impact:
- Understanding these platelet alterations is crucial for managing MPD complications.
- Current in vivo and in vitro platelet function tests are inadequate for early prediction of bleeding or thromboembolism in MPD.
- Further research is needed to develop reliable diagnostic and prognostic markers for MPD-associated platelet dysfunction.